Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Restructuring Costs

v3.20.1
Note 14 - Restructuring Costs
3 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]
1
4
.
Restructuring Costs
 
In
January 2019,
the Company implemented a strategic organizational realignment plan to reduce operating expenses and prepare the Company for expanded indications for its CMRF technology platform for improved sexual function and stress urinary incontinence in women. The restructuring included a reduction in headcount of approximately
40
full-time employees. The total restructuring costs were approximately
$742,000
and have been recorded in operating expenses in the condensed consolidated statements of operations. The restructuring contributed to a reduction in total operating expenses in the
first
quarter of
2019
as planned and resulted in additional operating cost savings throughout the remainder of this year.